Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
November 2016
-
In The NewsNew strategies for improving access in lower-income countriesHumanosphere highlights the work Novartis Access is doing to find a social enterprise solution to help patients in lower-income countries get access to medicines for chronic diseases.
-
Women in Science: Lilli Petruzzelli
A lung cancer researcher describes her journey toward a career in science at Novartis.
-
Media ReleaseNovartis Access communique son bilan à un an et annonce la signature d'un protocole d'accord avec le RwandaLe Rwanda devient le troisième pays à lancer Novartis Access, un programme de distribution de médicaments pour traiter les maladies chroniques dans les pays à faible revenu. Les premières livraisons…
-
Media ReleaseNovartis Access shares one-year learnings and announces memorandum of understanding with RwandaRwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than…
-
Media ReleaseNovartis Access informiert über Erfahrungen im ersten Jahr und gibt Memorandum of Understanding mit Ruanda bekanntRuanda ist das dritte Land, welches das Portfolio von Novartis Access gegen chronische Krankheiten einführen wird. Die ersten Medikamentenlieferungen sind für Anfang 2017 geplant. Seit September…
-
In The NewsNovartis Access one-year reportThe Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates,…
-
In The NewsTackling chronic disease with Novartis AccessChronic diseases like high blood pressure and diabetes impact more than just wealthy nations. Through the Novartis Foundation and Novartis Access, we’re working to address the rising threat of…
-
Women in Science: Hannah Mosca
Oncology Regulatory Affairs Leader Hannah Mosca describes her lifelong interest in science and math, and what it’s like to work at Novartis
-
Media ReleaseNovartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options Results of SUSTAIN will be…
-
Media ReleaseNovartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic COPD patients Bronchodilation regarded…
-
Media ReleaseInnovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originatorNo clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1] Innovative study design demonstrates switching between…
-
Media ReleaseNovartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine studySTRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
Pagination
- ‹ Previous page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- …
- 151
- › Next page